METABRIC

The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of the genome and transcriptome from representative numbers of patients. We present an integrated analysis of copy number and gene expression in a discovery and validation set of 997 and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants (CNVs, SNPs) and acquired somatic copy number aberrations (CNAs) were associated with expression in 40% of genes, although the landscape was dominated by cis and trans-acting CNAs. By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP, and MAP2K4. Unsupervised analysis of paired DNA/RNA profiles revealed novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort. These include a high-risk, ER-positive 11q13/14 cis-acting subgroup and a favourable prognosis subgroup devoid of CNAs. Trans-acting aberration 0152hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the 0152CNA-devoid sub-group and a Basal-specific chromosome 5 deletion-driven mitotic network. Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic copy number aberrations on the transcriptome.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

10 Datasets 242 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00010000162	Illumina HT 12 IDATS	Illumina HT 12	-
EGAD00010000164	Affymetrix 6.0 CEL files	Affymetrix SNP 6.0	-
EGAD00010000210	Normalized expression data; discovery set	Illumina HT 12	1
EGAD00010000211	Normalized expression data; validation set	Illumina HT 12	-
EGAD00010000212	Normalized expression data; normals	Illumina HT 12	-
EGAD00010000213	Segmented (CBS) copy number aberrations (CNA); discovery set	Affymetrix SNP 6.0	-
EGAD00010000214	Segmented (CBS) copy number variants (CNV); discovery set	Affymetrix SNP 6.0	-
EGAD00010000215	Segmented (CBS) copy number aberrations (CNA); validation set	Affymetrix SNP 6.0	-
EGAD00010000216	Segmented (CBS) copy number variants (CNV); validation set	Affymetrix SNP 6.0	-
EGAD00010000217	Segmented (HMM) copy number aberrations (CNA); discovery set	Affymetrix SNP 6.0	-

Publications	Citations
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. Nature 486: 2012 346-352	4034
Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Verhaak RG, Mills GB. Breast Cancer Res 14: 2012 322	1
Improving breast cancer survival analysis through competition-based multidimensional modeling. Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G, Sauerwine BA, Shimoni Y, Moen Vollan HK, Mecham BH, Rueda OM, Tost J, Curtis C, Alvarez MJ, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Califano A, Friend SH, Ideker T, Schadt EE, Stolovitzky GA, Margolin AA. PLoS Comput Biol 9: 2013 e1003047	58
The molecular diversity of Luminal A breast tumors. Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N. Breast Cancer Res Treat 141: 2013 409-420	94
The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Viré E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, Vidal A, Barbieri I, Aparicio S, Esteller M, Caldas C, Kouzarides T. Mol Cell 53: 2014 806-818	40
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL. BMC Cancer 14: 2014 211	25
Information content and analysis methods for multi-modal high-throughput biomedical data. Ray B, Henaff M, Ma S, Efstathiadis E, Peskin ER, Picone M, Poli T, Aliferis CF, Statnikov A. Sci Rep 4: 2014 4411	17
Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. Interiano RB, Yang J, Harris AL, Davidoff AM. J Surg Res 190: 2014 203-209	9
Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Doan TB, Eriksson NA, Graham D, Funder JW, Simpson ER, Kuczek ES, Clyne C, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL. Mol Oncol 8: 2014 998-1013	13
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Sizemore ST, Sizemore GM, Booth CN, Thompson CL, Silverman P, Bebek G, Abdul-Karim FW, Avril S, Keri RA. Breast Cancer Res Treat 146: 2014 25-40	26
Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations. Wang DY, Done SJ, Mc Cready DR, Leong WL. Breast Cancer Res 16: 2014 R71	6
Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Br J Cancer 111: 2014 1532-1541	74
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. J Natl Cancer Inst 106: 2014 dju152	148
Cancer progression modeling using static sample data. Sun Y, Yao J, Nowak NJ, Goodison S. Genome Biol 15: 2014 440	19
Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Ali HR, Rueda OM, Chin SF, Curtis C, Dunning MJ, Aparicio SA, Caldas C. Genome Biol 15: 2014 431	129
Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Hilton HN, Doan TB, Graham JD, Oakes SR, Silvestri A, Santucci N, Kantimm S, Huschtscha LI, Ormandy CJ, Funder JW, Simpson ER, Kuczek ES, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL. Oncotarget 5: 2014 8651-8664	20
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG. Nat Commun 5: 2014 5203	166
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HK, Vaske C, Siegel JU, Troyanskaya O, Chin SF, Caldas C, Balmain A, Børresen-Dale AL, Kristensen V. Mol Cancer Res 13: 2015 493-501	46
A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Burleigh A, McKinney S, Brimhall J, Yap D, Eirew P, Poon S, Ng V, Wan A, Prentice L, Annab L, Barrett JC, Caldas C, Eaves C, Aparicio S. Breast Cancer Res 17: 2015 4	19
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Cescon DW, Haibe-Kains B, Mak TW. Proc Natl Acad Sci U S A 112: 2015 2841-2846	106
Decreased <i>BECN1</i> mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, Hibshoosh H, Xiao G, Packer M, Xie Y, Levine B. EBioMedicine 2: 2015 255-263	88
Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. Khan S, Fagerholm R, Rafiq S, Tapper W, Aittomäki K, Liu J, Blomqvist C, Eccles D, Nevanlinna H. Clin Cancer Res 21: 2015 4086-4096	11
MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Phua YW, Nguyen A, Roden DL, Elsworth B, Deng N, Nikolic I, Yang J, Mcfarland A, Russell R, Kaplan W, Cowley MJ, Nair R, Zotenko E, O'Toole S, Tan SX, James DE, Clark SJ, Kouros-Mehr H, Swarbrick A. Breast Cancer Res 17: 2015 83	38
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. Milioli HH, Vimieiro R, Riveros C, Tishchenko I, Berretta R, Moscato P. PLoS One 10: 2015 e0129711	14
IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates. Ung MH, Varn FS, Cheng C. CPT Pharmacometrics Syst Pharmacol 4: 2015 415-425	3
An integrated network platform for contextual prioritization of drugs and pathways. Segura-Cabrera A, Singh N, Komurov K. Mol Biosyst 11: 2015 2850-2859	6
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Maley CC, Koelble K, Natrajan R, Aktipis A, Yuan Y. Breast Cancer Res 17: 2015 131	70
Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer. Liu C, Srihari S, Lal S, Gautier B, Simpson PT, Khanna KK, Ragan MA, Lê Cao KA. Mol Oncol 10: 2016 179-193	19
p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Zhuang T, Zhu J, Li Z, Lorent J, Zhao C, Dahlman-Wright K, Strömblad S. Oncotarget 6: 2015 43853-43868	34
Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells. Werner S, Stamm H, Pandjaitan M, Kemming D, Brors B, Pantel K, Wikman H. BMC Cancer 15: 2015 896	14
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, Irondelle M, Charruel M, Ducos B, Michaud A, Caron M, Marangoni E, Chavrier P, Le Tourneau C, Kamal M, Pasmant E, Vidaud M, Servant N, Reyal F, Meseure D, Vincent-Salomon A, Fre S, Margueron R. Genes Dev 29: 2015 2547-2562	64
YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, Blandino G. EMBO Rep 17: 2016 188-201	150
Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. Varn FS, Andrews EH, Mullins DW, Cheng C. Nat Commun 7: 2016 10248	38
Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset. Milioli HH, Vimieiro R, Tishchenko I, Riveros C, Berretta R, Moscato P. BioData Min 9: 2016 2	13
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, Bakal C, Yuan Y. PLoS Med 13: 2016 e1001961	83
Predicting chemoinsensitivity in breast cancer with 'omics/digital pathology data fusion. Savage RS, Yuan Y. R Soc Open Sci 3: 2016 140501	9
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH. Nat Cell Biol 18: 2016 632-644	161
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, Mohd Taib NA, Teo SH. Breast Cancer Res 18: 2016 56	39
Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Andradas C, Blasco-Benito S, Castillo-Lluva S, Dillenburg-Pilla P, Diez-Alarcia R, Juanes-García A, García-Taboada E, Hernando-Llorente R, Soriano J, Hamann S, Wenners A, Alkatout I, Klapper W, Rocken C, Bauer M, Arnold N, Quintanilla M, Megías D, Vicente-Manzanares M, Urigüen L, Gutkind JS, Guzmán M, Pérez-Gómez E, Sánchez C. Oncotarget 7: 2016 47565-47575	36
Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. Tishchenko I, Milioli HH, Riveros C, Moscato P. PLoS One 11: 2016 e0158259	13
Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci. Han MR, Long J, Choi JY, Low SK, Kweon SS, Zheng Y, Cai Q, Shi J, Guo X, Matsuo K, Iwasaki M, Shen CY, Kim MK, Wen W, Li B, Takahashi A, Shin MH, Xiang YB, Ito H, Kasuga Y, Noh DY, Matsuda K, Park MH, Gao YT, Iwata H, Tsugane S, Park SK, Kubo M, Shu XO, Kang D, Zheng W. Hum Mol Genet 25: 2016 3361-3371	29
Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Haider S, McIntyre A, van Stiphout RG, Winchester LM, Wigfield S, Harris AL, Buffa FM. Genome Biol 17: 2016 140	60
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, W Wood K, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW. Breast Cancer Res 18: 2016 70	12
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G. Nat Commun 7: 2016 12222	100
Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors. Wassef M, Michaud A, Margueron R. Cell Cycle 15: 2016 2256-2262	16
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. Bailey SD, Desai K, Kron KJ, Mazrooei P, Sinnott-Armstrong NA, Treloar AE, Dowar M, Thu KL, Cescon DW, Silvester J, Yang SY, Wu X, Pezo RC, Haibe-Kains B, Mak TW, Bedard PL, Pugh TJ, Sallari RC, Lupien M. Nat Genet 48: 2016 1260-1266	66
Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis. Ung MH, Wang GL, Varn FS, Cheng C. Oncotarget 7: 2016 84142-84154	4
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T. Oncotarget 7: 2016 51012-51026	22
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS. Nat Commun 7: 2016 12991	49
Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium. Daly CS, Shaw P, Ordonez LD, Williams GT, Quist J, Grigoriadis A, Van Es JH, Clevers H, Clarke AR, Reed KR. Oncogene 36: 2017 1793-1803	21
Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. Wolf B, Goebel G, Hackl H, Fiegl H. BMC Cancer 16: 2016 821	20
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN. Nat Med 22: 2016 1303-1313	154
Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. Wang Y, Mark KM, Ung MH, Kettenbach A, Miller T, Xu W, Cheng W, Xia T, Cheng C. Genome Med 8: 2016 114	3
Unique epigenetic gene profiles define human breast cancers with poor prognosis. Peña-Llopis S, Wan Y, Martinez ED. Oncotarget 7: 2016 85819-85831	12
Contextual Refinement of Regulatory Targets Reveals Effects on Breast Cancer Prognosis of the Regulome. Andrews E, Wang Y, Xia T, Cheng W, Cheng C. PLoS Comput Biol 13: 2017 e1005340	5
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Bierie B, Pierce SE, Kroeger C, Stover DG, Pattabiraman DR, Thiru P, Liu Donaher J, Reinhardt F, Chaffer CL, Keckesova Z, Weinberg RA. Proc Natl Acad Sci U S A 114: 2017 E2337-E2346	231
A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Erdal E, Haider S, Rehwinkel J, Harris AL, McHugh PJ. Genes Dev 31: 2017 353-369	161
Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. Foroushani A, Agrahari R, Docking R, Chang L, Duns G, Hudoba M, Karsan A, Zare H. BMC Med Genomics 10: 2017 16	37
Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. Milioli HH, Tishchenko I, Riveros C, Berretta R, Moscato P. BMC Med Genomics 10: 2017 19	65
Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer. Yang C, Zhao X, Cui N, Liang Y. Stem Cells Int 2017: 2017 5091541	19
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM. Genes Dev 31: 2017 553-566	74
Regulatory network of GATA3 in pediatric acute lymphoblastic leukemia. Hou Q, Liao F, Zhang S, Zhang D, Zhang Y, Zhou X, Xia X, Ye Y, Yang H, Li Z, Wang L, Wang X, Ma Z, Zhu Y, Ouyang L, Wang Y, Zhang H, Yang L, Xu H, Shu Y. Oncotarget 8: 2017 36040-36053	15
Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. Hu S, Yuan H, Li Z, Zhang J, Wu J, Chen Y, Shi Q, Ren W, Shao N, Ying X. Oncotarget 8: 2017 41334-41347	21
Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. Mucaki EJ, Baranova K, Pham HQ, Rezaeian I, Angelov D, Ngom A, Rueda L, Rogan PK. F1000Res 5: 2016 2124	19
The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, De Panfilis S, Fazi F, Bates DO, Bicciato S, Zylicz M, Zylicz A, Blandino G, Fontemaggi G. EMBO Rep 18: 2017 1331-1351	77
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG. Oncotarget 8: 2017 57121-57133	27
A role for Tau protein in maintaining ribosomal DNA stability and cytidine deaminase-deficient cell survival. Bou Samra E, Buhagiar-Labarchède G, Machon C, Guitton J, Onclercq-Delic R, Green MR, Alibert O, Gazin C, Veaute X, Amor-Guéret M. Nat Commun 8: 2017 693	29
Up For A Challenge (U4C): Stimulating innovation in breast cancer genetic epidemiology. Mechanic LE, Lindström S, Daily KM, Sieberts SK, Amos CI, Chen HS, Cox NJ, Dathe M, Feuer EJ, Guertin MJ, Hoffman J, Liu Y, Moore JH, Myers CL, Ritchie MD, Schildkraut J, Schumacher F, Witte JS, Wang W, Williams SM, U4C Challenge Participants, U4C Challenge Data Contributors, Gillanders EM. PLoS Genet 13: 2017 e1006945	3
A novel approach for data integration and disease subtyping. Nguyen T, Tagett R, Diaz D, Draghici S. Genome Res 27: 2017 2025-2039	90
Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding. Knopfová L, Biglieri E, Volodko N, Masařík M, Hermanová M, Glaus Garzón JF, Dúcka M, Kučírková T, Souček K, Šmarda J, Beneš P, Borsig L. Oncogene 37: 2018 1020-1030	17
Cancer cell line specific co-factors modulate the FOXM1 cistrome. Wang Y, Ung MH, Xia T, Cheng W, Cheng C. Oncotarget 8: 2017 76498-76515	8
Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Wang Y, Ung MH, Cantor S, Cheng C. Sci Rep 7: 2017 15742	8
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. Quigley DA, Tahiri A, Lüders T, Riis MH, Balmain A, Børresen-Dale AL, Bukholm I, Kristensen V. Oncoimmunology 6: 2017 e1356142	30
Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K. Front Immunol 8: 2017 1412	75
Identification of cancer genes that are independent of dominant proliferation and lineage programs. Selfors LM, Stover DG, Harris IS, Brugge JS, Coloff JL. Proc Natl Acad Sci U S A 114: 2017 E11276-E11284	17
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, Severino LU, Scaini D, Mano M, Mantovani F, Rosato A, Bicciato S, Piccolo S, Del Sal G. Nat Cell Biol 20: 2018 28-35	100
miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ. Breast Cancer Res 19: 2017 133	95
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW. J Exp Med 215: 2018 895-910	45
MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, Miluzio A, Gaudioso G, Vaira V, Turdo A, Gaggianesi M, Chinnici A, Lipari E, Bicciato S, Bosari S, Todaro M, Zippo A. Nat Commun 9: 2018 1024	109
Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. Baxter JS, Leavy OC, Dryden NH, Maguire S, Johnson N, Fedele V, Simigdala N, Martin LA, Andrews S, Wingett SW, Assiotis I, Fenwick K, Chauhan R, Rust AG, Orr N, Dudbridge F, Haider S, Fletcher O. Nat Commun 9: 2018 1028	73
Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. Mukherjee A, Russell R, Chin SF, Liu B, Rueda OM, Ali HR, Turashvili G, Mahler-Araujo B, Ellis IO, Aparicio S, Caldas C, Provenzano E. NPJ Breast Cancer 4: 2018 5	29
Recurrent copy number alterations in young women with breast cancer. Chi C, Murphy LC, Hu P. Oncotarget 9: 2018 11541-11558	7
Applications of Bayesian network models in predicting types of hematological malignancies. Agrahari R, Foroushani A, Docking TR, Chang L, Duns G, Hudoba M, Karsan A, Zare H. Sci Rep 8: 2018 6951	35
A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. Guo X, Lin W, Bao J, Cai Q, Pan X, Bai M, Yuan Y, Shi J, Sun Y, Han MR, Wang J, Liu Q, Wen W, Li B, Long J, Chen J, Zheng W. Am J Hum Genet 102: 2018 890-903	66
SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways. Zohrap N, Saatci Ö, Ozes B, Coban I, Atay HM, Battaloglu E, Şahin Ö, Bugra K. Oncotarget 9: 2018 21876-21892	21
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, Mills GB, Brugge JS. Cancer Cell 33: 2018 985-1003.e7	164
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W. Cell Metab 28: 2018 87-103.e6	285
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ. Oncogene 37: 2018 5701-5718	26
Combining Pathway Identification and Breast Cancer Survival Prediction via Screening-Network Methods. Iuliano A, Occhipinti A, Angelini C, De Feis I, Liò P. Front Genet 9: 2018 206	6
SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis. Vervoort SJ, Lourenço AR, Tufegdzic Vidakovic A, Mocholi E, Sandoval JL, Rueda OM, Frederiks C, Pals C, Peeters JGC, Caldas C, Bruna A, Coffer PJ. Nucleic Acids Res 46: 2018 9578-9590	36
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER<sup>+</sup> breast cancer. Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW. FASEB J 33: 2019 1644-1657	13
Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. Geeleher P, Nath A, Wang F, Zhang Z, Barbeira AN, Fessler J, Grossman RL, Seoighe C, Stephanie Huang R. Genome Biol 19: 2018 130	23
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A. Mol Cancer Ther 18: 2019 204-212	17
Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival. Zhang L, Feizi N, Chi C, Hu P. Front Genet 9: 2018 421	31
Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. Bismeijer T, Canisius S, Wessels LFA. PLoS Comput Biol 14: 2018 e1006520	8
Hunt for the tipping point during endocrine resistance process in breast cancer by dynamic network biomarkers. Liu R, Wang J, Ukai M, Sewon K, Chen P, Suzuki Y, Wang H, Aihara K, Okada-Hatakeyama M, Chen L. J Mol Cell Biol 11: 2019 649-664	38
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD. Oncoimmunology 7: 2018 e1490854	166
A comparative study of survival models for breast cancer prognostication revisited: the benefits of multi-gene models. Grzadkowski MR, Sendorek DH, P'ng C, Huang V, Boutros PC. BMC Bioinformatics 19: 2018 400	5
An assessment of prognostic immunity markers in breast cancer. Yang B, Chou J, Tao Y, Wu D, Wu X, Li X, Li Y, Chu Y, Tang F, Shi Y, Ma L, Zhou T, Kaufmann W, Carey LA, Wu J, Hu Z. NPJ Breast Cancer 4: 2018 35	31
Pathway-based subnetworks enable cross-disease biomarker discovery. Haider S, Yao CQ, Sabine VS, Grzadkowski M, Stimper V, Starmans MHW, Wang J, Nguyen F, Moon NC, Lin X, Drake C, Crozier CA, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW, Kasprzyk A, Lambin P, Lambin P, Lio' P, Bartlett JMS, Boutros PC. Nat Commun 9: 2018 4746	21
Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. Vervoort SJ, de Jong OG, Roukens MG, Frederiks CL, Vermeulen JF, Lourenço AR, Bella L, Vidakovic AT, Sandoval JL, Moelans C, van Amersfoort M, Dallman MJ, Bruna A, Caldas C, Nieuwenhuis E, van der Wall E, Derksen P, van Diest P, Verhaar MC, Lam EW, Mokry M, Coffer PJ. Elife 7: 2018 e27706	37
Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Bartoschek M, Oskolkov N, Bocci M, Lövrot J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pekar G, Karlsson G, Ringnér M, Bergh J, Björklund Å, Pietras K. Nat Commun 9: 2018 5150	526
FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K. EBioMedicine 39: 2019 226-238	31
Identifying genes with tri-modal association with survival and tumor grade in cancer patients. Zhang M, Wang T, Sirianni R, Shaul PW, Xie Y. BMC Bioinformatics 20: 2019 13	0
A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E. Breast Cancer Res 21: 2019 18	30
pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation. Sonnenblick A, Venet D, Brohée S, Pondé N, Sotiriou C. NPJ Breast Cancer 5: 2019 7	16
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. Lundberg A, Lindström LS, Li J, Harrell JC, Darai-Ramqvist E, Sifakis EG, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP. Breast Cancer Res 21: 2019 34	37
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C. Nature 567: 2019 399-404	245
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A. PLoS One 14: 2019 e0209134	18
Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail. Lu L, Chen Z, Lin X, Tian L, Su Q, An P, Li W, Wu Y, Du J, Shan H, Chiang CM, Wang H. Cell Death Differ 27: 2020 255-268	78
Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment. Pachynski RK, Wang P, Salazar N, Zheng Y, Nease L, Rosalez J, Leong WI, Virdi G, Rennier K, Shin WJ, Nguyen V, Butcher EC, Zabel BA. Front Immunol 10: 2019 983	46
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G. Cancer Cell 35: 2019 885-900.e10	514
LobSig is a multigene predictor of outcome in invasive lobular carcinoma. McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, Kalita-de Croft P, Dalley AJ, Coorey CP, Kuo L, Ferguson K, Niland C, Miller G, Johnson J, Reid LE, Males R, Saunus JM, Chenevix-Trench G, Coin L, Lakhani SR, Simpson PT. NPJ Breast Cancer 5: 2019 18	32
Landscape of transcriptomic interactions between breast cancer and its microenvironment. Fox NS, Haider S, Harris AL, Boutros PC. Nat Commun 10: 2019 3116	18
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. Mazumdar A, Tahaney WM, Reddy Bollu L, Poage G, Hill J, Zhang Y, Mills GB, Brown PH. NPJ Breast Cancer 5: 2019 22	16
Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types. Hjaltelin JX, Izarzugaza JMG, Jensen LJ, Russo F, Westergaard D, Brunak S. NPJ Syst Biol Appl 5: 2019 27	11
PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer. Costa TDF, Zhuang T, Lorent J, Turco E, Olofsson H, Masia-Balague M, Zhao M, Rabieifar P, Robertson N, Kuiper R, Sjölund J, Spiess M, Hernández-Varas P, Rabenhorst U, Roswall P, Ma R, Gong X, Hartman J, Pietras K, Adams PD, Defilippi P, Strömblad S. Nat Commun 10: 2019 3589	26
Single-cell landscape in mammary epithelium reveals bipotent-like cells associated with breast cancer risk and outcome. Chen W, Morabito SJ, Kessenbrock K, Enver T, Meyer KB, Teschendorff AE. Commun Biol 2: 2019 306	43
High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival. Zhang Y, Yang WK, Wen GM, Tang H, Wu CA, Wu YX, Jing ZL, Tang MS, Liu GL, Li DZ, Li YH, Deng YJ. Mol Genet Genomic Med 7: 2019 e908	29
Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. Allott EH, Shan Y, Chen M, Sun X, Garcia-Recio S, Kirk EL, Olshan AF, Geradts J, Earp HS, Carey LA, Perou CM, Pfeiffer RM, Anderson WF, Troester MA. Breast Cancer Res Treat 179: 2020 185-195	15
Star-PAP regulates tumor protein D52 through modulating miR-449a/34a in breast cancer. Duan A, Kong L, An T, Zhou H, Yu C, Li Y. Biol Open 8: 2019 bio045914	2
Transcriptional Signature Derived from Murine Tumor-Associated Macrophages Correlates with Poor Outcome in Breast Cancer Patients. Tuit S, Salvagno C, Kapellos TS, Hau CS, Seep L, Oestreich M, Klee K, de Visser KE, Ulas T, Schultze JL. Cell Rep 29: 2019 1221-1235.e5	26
PathTracer: High-sensitivity detection of differential pathway activity in tumours. Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD. Sci Rep 9: 2019 16332	3
Human gene expression variability and its dependence on methylation and aging. Bashkeel N, Perkins TJ, Kærn M, Lee JM. BMC Genomics 20: 2019 941	19
Androgen receptor gene expression in primary breast cancer. Vidula N, Yau C, Wolf D, Rugo HS. NPJ Breast Cancer 5: 2019 47	25
A transcriptome-based signature of pathological angiogenesis predicts breast cancer patient survival. Guarischi-Sousa R, Monteiro JS, Alecrim LC, Michaloski JS, Cardeal LB, Ferreira EN, Carraro DM, Nunes DN, Dias-Neto E, Reimand J, Boutros PC, Setubal JC, Giordano RJ. PLoS Genet 15: 2019 e1008482	10
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. Cell Rep 29: 2019 4389-4406.e10	55
Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. Li AM, Ducker GS, Li Y, Seoane JA, Xiao Y, Melemenidis S, Zhou Y, Liu L, Vanharanta S, Graves EE, Rankin EB, Curtis C, Massagué J, Rabinowitz JD, Thompson CB, Ye J. Mol Cancer Res 18: 2020 599-611	51
Chromosome arm aneuploidies shape tumour evolution and drug response. Shukla A, Nguyen THM, Moka SB, Ellis JJ, Grady JP, Oey H, Cristino AS, Khanna KK, Kroese DP, Krause L, Dray E, Fink JL, Duijf PHG. Nat Commun 11: 2020 449	72
Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. Chen J, Ye C, Dong J, Cao S, Hu Y, Situ B, Xi X, Qin S, Xu J, Cai Z, Zheng L, Wang Q. J Transl Med 18: 2020 59	26
Breast cancer survival and the expression of genes related to alcohol drinking. Cheng HG, Gonzalez-Reymundez A, Li I, Pathak A, Pathak DR, de Los Campos G, Vazquez AI. PLoS One 15: 2020 e0228957	4
Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Shu X, Long J, Cai Q, Kweon SS, Choi JY, Kubo M, Park SK, Bolla MK, Dennis J, Wang Q, Yang Y, Shi J, Guo X, Li B, Tao R, Aronson KJ, Chan KYK, Chan TL, Gao YT, Hartman M, Kee Ho W, Ito H, Iwasaki M, Iwata H, John EM, Kasuga Y, Soon Khoo U, Kim MK, Kong SY, Kurian AW, Kwong A, Lee ES, Li J, Lophatananon A, Low SK, Mariapun S, Matsuda K, Matsuo K, Muir K, Noh DY, Park B, Park MH, Shen CY, Shin MH, Spinelli JJ, Takahashi A, Tseng C, Tsugane S, Wu AH, Xiang YB, Yamaji T, Zheng Y, Milne RL, Dunning AM, Pharoah PDP, García-Closas M, Teo SH, Shu XO, Kang D, Easton DF, Simard J, Zheng W. Nat Commun 11: 2020 1217	53
TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-β signaling. Nyati S, Gregg BS, Xu J, Young G, Kimmel L, Nyati MK, Ray D, Speers C, Rehemtulla A. Neoplasia 22: 2020 163-178	8
Pan-cancer systematic identification of lncRNAs associated with cancer prognosis. Ung M, Schaafsma E, Mattox D, Wang GL, Cheng C. PeerJ 8: 2020 e8797	2
Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence. Peng C, Heng YJ, Lu D, DuPre NC, Kensler KH, Glass K, Zeleznik OA, Kraft P, Feldman D, Hankinson SE, Rexrode K, Eliassen AH, Tamimi RM. Cancer Epidemiol Biomarkers Prev 29: 2020 1253-1263	5
DNA copy number motifs are strong and independent predictors of survival in breast cancer. Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC. Commun Biol 3: 2020 153	11
A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients. Li J, Jiang W, Liang Q, Liu G, Dai Y, Zheng H, Yang J, Cai H, Zheng G. BMC Genomics 21: 2020 283	3
Stromal Platelet-Derived Growth Factor Receptor-β Signaling Promotes Breast Cancer Metastasis in the Brain. Thies KA, Hammer AM, Hildreth BE, Steck SA, Spehar JM, Kladney RD, Geisler JA, Das M, Russell LO, Bey JF, Bolyard CM, Pilarski R, Trimboli AJ, Cuitiño MC, Koivisto CS, Stover DG, Schoenfield L, Otero J, Godbout JP, Chakravarti A, Ringel MD, Ramaswamy B, Li Z, Kaur B, Leone G, Ostrowski MC, Sizemore ST, Sizemore GM. Cancer Res 81: 2021 606-618	33
LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target. Hagerling C, Owyong M, Sitarama V, Wang CY, Lin C, van den Bijgaart RJE, Koopman CD, Brenot A, Nanjaraj A, Wärnberg F, Jirström K, Klein OD, Werb Z, Plaks V. BMC Cancer 20: 2020 542	36
The transcriptional repressor BCL11A promotes breast cancer metastasis. Seachrist DD, Hannigan MM, Ingles NN, Webb BM, Weber-Bonk KL, Yu P, Bebek G, Singh S, Sizemore ST, Varadan V, Licatalosi DD, Keri RA. J Biol Chem 295: 2020 11707-11719	20
Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Pommier RM, Sanlaville A, Tonon L, Kielbassa J, Thomas E, Ferrari A, Sertier AS, Hollande F, Martinez P, Tissier A, Morel AP, Ouzounova M, Puisieux A. Nat Commun 11: 2020 3431	67
Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer. Tahiri A, Tekpli X, Satheesh SV, DeWijn R, Lüders T, Bukholm IR, Hurtado A, Geisler J, Kristensen VN. Breast Cancer Res Treat 183: 2020 585-598	11
Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer. Feng Y, Guo C, Wang H, Zhao L, Wang W, Wang T, Feng Y, Yuan K, Huang G. Med Sci Monit 26: 2020 e923531	14
A novel single-cell based method for breast cancer prognosis. Li X, Liu L, Goodall GJ, Schreiber A, Xu T, Li J, Le TD. PLoS Comput Biol 16: 2020 e1008133	17
Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. Morotti M, Zois CE, El-Ansari R, Craze ML, Rakha EA, Fan SJ, Valli A, Haider S, Goberdhan DCI, Green AR, Harris AL. Br J Cancer 124: 2021 494-505	76
CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. Zhao Y, Pan Z, Namburi S, Pattison A, Posner A, Balachander S, Paisie CA, Reddi HV, Rueter J, Gill AJ, Fox S, Raghav KPS, Flynn WF, Tothill RW, Li S, Karuturi RKM, George J. EBioMedicine 61: 2020 103030	58
Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression. Heng B, Bilgin AA, Lovejoy DB, Tan VX, Milioli HH, Gluch L, Bustamante S, Sabaretnam T, Moscato P, Lim CK, Guillemin GJ. Breast Cancer Res 22: 2020 113	37
A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer. Doan TB, Cheung V, Clyne CD, Hilton HN, Eriksson N, Young MJ, Funder JW, Muscat GEO, Fuller PJ, Clarke CL, Graham JD. Breast Cancer Res 22: 2020 122	9
Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Bieging-Rolett KT, Kaiser AM, Morgens DW, Boutelle AM, Seoane JA, Van Nostrand EL, Zhu C, Houlihan SL, Mello SS, Yee BA, McClendon J, Pierce SE, Winters IP, Wang M, Connolly AJ, Lowe SW, Curtis C, Yeo GW, Winslow MM, Bassik MC, Attardi LD. Mol Cell 80: 2020 452-469.e9	62
A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer. Li N, Cai H, Song K, Guo Y, Liang Q, Zhang J, Chen R, Li J, Wang X, Guo Z. Front Genet 11: 2020 566928	3
Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer. Iqbal MA, Siddiqui S, Ur Rehman A, Siddiqui FA, Singh P, Kumar B, Saluja D. Mol Oncol 15: 2021 1450-1465	28
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N. Oncoimmunology 9: 2020 1824644	24
High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. Nair MG, Prabhu JS, Ts S. Cancer Treat Res Commun 27: 2021 100321	12
Up-regulation of L Antigen Family Member 3 Associates With Aggressive Progression of Breast Cancer. Dong X, Lv S, Gu D, Zhang X, Ye Z. Front Oncol 10: 2020 553628	3
eTumorMetastasis: A Network-based Algorithm Predicts Clinical Outcomes Using Whole-exome Sequencing Data of Cancer Patients. Milanese JS, Tibiche C, Zaman N, Zou J, Han P, Meng Z, Nantel A, Droit A, Wang E. Genomics Proteomics Bioinformatics 19: 2021 973-985	5
Widespread Alternative Splicing Changes in Metastatic Breast Cancer Cells. Oh J, Pradella D, Shao C, Li H, Choi N, Ha J, Ruggiero S, Fu XD, Zheng X, Ghigna C, Shen H. Cells 10: 2021 858	11
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, Pernas S, Muñoz M, Vidal MJ, Margelí Vila M, Cejalvo JM, González-Farré B, Espinosa-Bravo M, Cruz J, Salvador-Bofill FJ, Guerra JA, Luna Barrera AM, Arumi de Dios M, Esker S, Fan PD, Martínez-Sáez O, Villacampa G, Paré L, Ferrero-Cafiero JM, Villagrasa P, Prat A. Front Oncol 11: 2021 638482	17
Genomic features of rapid versus late relapse in triple negative breast cancer. Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. BMC Cancer 21: 2021 568	19
Uncovering the roles of microRNAs/lncRNAs in characterising breast cancer subtypes and prognosis. Li X, Truong B, Xu T, Liu L, Li J, Le TD. BMC Bioinformatics 22: 2021 300	3
IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment. Clark AM, Heusey HL, Griffith LG, Lauffenburger DA, Wells A. Front Oncol 11: 2021 676135	27
Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer. Zeng R, Mohamed A, Khanna KK, Hill MM. Cancers (Basel) 13: 2021 3330	2
MultiK: an automated tool to determine optimal cluster numbers in single-cell RNA sequencing data. Liu S, Thennavan A, Garay JP, Marron JS, Perou CM. Genome Biol 22: 2021 232	23
DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Batra RN, Lifshitz A, Vidakovic AT, Chin SF, Sati-Batra A, Sammut SJ, Provenzano E, Ali HR, Dariush A, Bruna A, Murphy L, Purushotham A, Ellis I, Green A, Garrett-Bakelman FE, Mason C, Melnick A, Aparicio SAJR, Rueda OM, Tanay A, Caldas C. Nat Commun 12: 2021 5406	40
Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Wen W, Chen Z, Bao J, Long Q, Shu XO, Zheng W, Guo X. Nat Commun 12: 2021 5318	18
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. Horr C, Buechler SA. NPJ Breast Cancer 7: 2021 136	20
Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Su K, Yu Q, Shen R, Sun SY, Moreno CS, Li X, Qin ZS. Cell Rep Methods 1: 2021 100050	13
From Cellular Infiltration Assessment to a Functional Gene Set-Based Prognostic Model for Breast Cancer. Li H, Huang Y, Sharma A, Ming W, Luo K, Gu Z, Sun X, Liu H. Front Immunol 12: 2021 751530	5
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers. Cicek E, Circir A, Oyken M, Akbulut Caliskan O, Dioken DN, Guntekin Ergun S, Cetin-Atalay R, Sapmaz A, Ovaa H, Sahin O, Erson-Bensan AE. Oncogene 41: 2022 220-232	11
TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis. Hu J, Lai Y, Huang H, Ramakrishnan S, Pan Y, Ma VWS, Cheuk W, So GYK, He Q, Geoffrey Lau C, Zhang L, Cho WCS, Chan KM, Wang X, Rebecca Chin Y. Br J Cancer 126: 2022 57-71	15
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, Gonzalez-Ericsson PI, Sanders ME, Zhang B, Pietenpol JA, Chen XS. Nat Commun 12: 2021 6276	131
Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach. Mercatelli D, Formaggio F, Caprini M, Holding A, Giorgi FM. Biosci Rep 41: 2021 BSR20212218	6
ENTREP/FAM189A2 encodes a new ITCH ubiquitin ligase activator that is downregulated in breast cancer. Tsunoda T, Riku M, Yamada N, Tsuchiya H, Tomita T, Suzuki M, Kizuki M, Inoko A, Ito H, Murotani K, Murakami H, Saeki Y, Kasai K. EMBO Rep 23: 2022 e51182	12
oCEM: Automatic detection and analysis of overlapping co-expressed gene modules. Nguyen QH, Le DH. BMC Genomics 23: 2022 39	3
Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer. Egelston CA, Guo W, Tan J, Avalos C, Simons DL, Lim MH, Huang YJ, Nelson MS, Chowdhury A, Schmolze DB, Yim JH, Kruper L, Melstrom L, Margolin K, Mortimer JE, Yuan Y, Waisman JR, Lee PP. JCI Insight 7: 2022 e153963	22
A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction. Yao K, Tong CY, Cheng C. Sci Rep 12: 2022 2211	7
Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature. Tschodu D, Ulm B, Bendrat K, Lippoldt J, Gottheil P, Käs JA, Niendorf A. PLoS One 17: 2022 e0261035	6
High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level. Luo M, Fu A, Wu R, Wei N, Song K, Lim S, Luo KQ. Int J Biol Sci 18: 2022 1120-1133	24
DrGA: cancer driver gene analysis in a simpler manner. Nguyen QH, Nguyen T, Le DH. BMC Bioinformatics 23: 2022 86	1
Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer. Yao K, Schaafsma E, Zhang B, Cheng C. PLoS Comput Biol 18: 2022 e1009495	0
miR-126 Decreases Proliferation and Mammosphere Formation of MCF-7 and Predicts Prognosis of ER+ Breast Cancer. Msheik ZS, Nassar FJ, Chamandi G, Itani AR, Gadaleta E, Chalala C, Alwan N, Nasr RR. Diagnostics (Basel) 12: 2022 745	9
Survival analysis of pathway activity as a prognostic determinant in breast cancer. Jeuken GS, Tobin NP, Käll L. PLoS Comput Biol 18: 2022 e1010020	2
Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer. Ankill J, Aure MR, Bjørklund S, Langberg S, Oslo Breast Cancer Consortium (OSBREAC) , Kristensen VN, Vitelli V, Tekpli X, Fleischer T. NAR Cancer 4: 2022 zcac008	11
BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer. Cabarcas-Petroski S, Schramm L. Cancers (Basel) 14: 2022 1658	4
Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Danenberg E, Bardwell H, Zanotelli VRT, Provenzano E, Chin SF, Rueda OM, Green A, Rakha E, Aparicio S, Ellis IO, Bodenmiller B, Caldas C, Ali HR. Nat Genet 54: 2022 660-669	142
Computationally repurposing drugs for breast cancer subtypes using a network-based approach. Firoozbakht F, Rezaeian I, Rueda L, Ngom A. BMC Bioinformatics 23: 2022 143	7
Molecular analysis of TCGA breast cancer histologic types. Thennavan A, Beca F, Xia Y, Recio SG, Allison K, Collins LC, Tse GM, Chen YY, Schnitt SJ, Hoadley KA, Beck A, Perou CM. Cell Genom 1: 2021 100067	63
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. Saunus JM, De Luca XM, Northwood K, Raghavendra A, Hasson A, McCart Reed AE, Lim M, Lal S, Vargas AC, Kutasovic JR, Dalley AJ, Miranda M, Kalaw E, Kalita-de Croft P, Gresshoff I, Al-Ejeh F, Gee JMW, Ormandy C, Khanna KK, Beesley J, Chenevix-Trench G, Green AR, Rakha EA, Ellis IO, Nicolau DV, Simpson PT, Lakhani SR. NPJ Breast Cancer 8: 2022 57	11
Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Nat Biotechnol 40: 2022 1624-1633	47
Delineation of Pathogenomic Insights of Breast Cancer in Young Women. Paul AM, George B, Saini S, Pillai MR, Toi M, Costa L, Kumar R. Cells 11: 2022 1927	7
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. Nat Commun 13: 2022 3671	35
Differential Private Deep Learning Models for Analyzing Breast Cancer Omics Data. Islam MM, Mohammed N, Wang Y, Hu P. Front Oncol 12: 2022 879607	4
Comparative Analysis of Gene Correlation Networks of Breast Cancer Patients Based on Mutations in TP53. Park B, Im J, Han K. Biomolecules 12: 2022 979	1
A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer. Ingebriktsen LM, Finne K, Akslen LA, Wik E. Br J Cancer 127: 2022 1865-1875	7
ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. McKernan CM, Khatri A, Hannigan M, Child J, Chen Q, Mayro B, Snyder D, Nicchitta CV, Pendergast AM. Cell Rep 40: 2022 111268	4
Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors. Kieu TL, Pierre L, Derangère V, Perrey S, Truntzer C, Jalil A, Causse S, Groetz E, Dumont A, Guyard L, Arnould L, de Barros JP, Apetoh L, Rébé C, Limagne E, Jourdan T, Demizieux L, Masson D, Thomas C, Ghiringhelli F, Rialland M. Cell Death Dis 13: 2022 758	16
RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer. Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA. Cancer Epidemiol Biomarkers Prev 31: 2022 2136-2147	12
NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. Di Benedetto C, Oh J, Choudhery Z, Shi W, Valdes G, Betancur P. BMC Cancer 22: 2022 1056	7
Hierarchical Ridge Regression for Incorporating Prior Information in Genomic Studies. Kawaguchi ES, Li S, Weaver GM, Lewinger JP. J Data Sci 20: 2022 34-50	3
Identification of novel genes for triple-negative breast cancer with semiparametric gene-based analysis. Liu X, Tian G, Liu Z. J Appl Stat 50: 2023 691-702	1
Kindlin-1 regulates IL-6 secretion and modulates the immune environment in breast cancer models. Webb ER, Dodd GL, Noskova M, Bullock E, Muir M, Frame MC, Serrels A, Brunton VG. Elife 12: 2023 e85739	7
A positive feedback loop driven by fibronectin and IL-1β sustains the inflammatory microenvironment in breast cancer. Tunali G, Yanik H, Ozturk SC, Demirkol-Canli S, Efthymiou G, Yilmaz KB, Van Obberghen-Schilling E, Esendagli G. Breast Cancer Res 25: 2023 27	4
Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population. Hamilton AM, Van Alsten SC, Gao X, Nsonwu-Farley J, Calhoun BC, Love MI, Troester MA, Hoadley KA. Cancer Res Commun 3: 2023 12-20	4
A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression. Culbertson B, Garcia K, Markett D, Asgharian H, Chen L, Fish L, Navickas A, Yu J, Woo B, Nanda AS, Choi B, Zhou S, Rabinowitz J, Goodarzi H. Nat Cancer 4: 2023 682-698	16
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer. Wiecek AJ, Cutty SJ, Kornai D, Parreno-Centeno M, Gourmet LE, Tagliazucchi GM, Jacobson DH, Zhang P, Xiong L, Bond GL, Barr AR, Secrier M. Genome Biol 24: 2023 128	40
Hypoxia induced responses are reflected in the stromal proteome of breast cancer. Kjølle S, Finne K, Birkeland E, Ardawatia V, Winge I, Aziz S, Knutsvik G, Wik E, Paulo JA, Vethe H, Kleftogiannis D, Akslen LA. Nat Commun 14: 2023 3724	6
Dissecting molecular, pathological, and clinical features associated with tumor neural/neuroendocrine heterogeneity. Cai L, DeBerardinis RJ, Xiao G, Minna JD, Xie Y. iScience 26: 2023 106983	1
SUPREME: multiomics data integration using graph convolutional networks. Kesimoglu ZN, Bozdag S. NAR Genom Bioinform 5: 2023 lqad063	7
Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors. Kim H, Whitman AA, Wisniewska K, Kakati RT, Garcia-Recio S, Calhoun BC, Franco HL, Perou CM, Spanheimer PM. Clin Cancer Res 29: 2023 4894-4907	5
An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response. Dioken DN, Ozgul I, Yilmazbilek I, Yakicier MC, Karaca E, Erson-Bensan AE. Cancer Immunol Immunother 72: 2023 4065-4075	1
Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy. Santamaria G, Cioce M, Rizzuto A, Fazio VM, Viglietto G, Lucibello M. Cancer Drug Resist 6: 2023 447-467	2
Metabolic stratification of human breast tumors reveal subtypes of clinical and therapeutic relevance. Iqbal MA, Siddiqui S, Smith K, Singh P, Kumar B, Chouaib S, Chandrasekaran S. iScience 26: 2023 108059	4
Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth. Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, Cancila V, Vacca D, Caputo M, Donzelli S, Segatto I, Vodret S, Piazza S, Rustighi A, Mantovani F, Belletti B, Baldassarre G, Blandino G, Tripodo C, Bicciato S, Mitro N, Del Sal G. Nat Commun 14: 2023 6777	21
HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment. Jacobs C, Shah S, Lu WC, Ray H, Wang J, Hockaden N, Sandusky G, Nephew KP, Lu X, Cao S, Carpenter RL. Cancer Res 84: 2024 276-290	18
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Ahn S, Park JH, Grimm SL, Piyarathna DWB, Samanta T, Putluri V, Mezquita D, Fuqua SAW, Putluri N, Coarfa C, Kaipparettu BA. Cancer Res 84: 2024 291-304	16
MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis. Llorente A, Blasco MT, Espuny I, Guiu M, Ballaré C, Blanco E, Caballé A, Bellmunt A, Salvador F, Morales A, Nuñez M, Loren G, Imbastari F, Fidalgo M, Figueras-Puig C, Gibler P, Graupera M, Monteiro F, Riera A, Holen I, Avgustinova A, Di Croce L, Gomis RR. Nat Cell Biol 25: 2023 1833-1847	2
GRB2 is a BECN1 interacting protein that regulates autophagy. Montero-Vergara J, Plachetta K, Kinch L, Bernhardt S, Kashyap K, Levine B, Thukral L, Vetter M, Thomssen C, Wiemann S, Peña-Llopis S, Jendrossek V, Vega-Rubin-de-Celis S. Cell Death Dis 15: 2024 14	4
Pathway analysis through mutual information. Jeuken GS, Käll L. Bioinformatics 40: 2024 btad776	2
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer. Corné J, Quillien V, Godey F, Cherel M, Cochet A, Le Du F, Robert L, Bourien H, Brunot A, Crouzet L, Perrin C, Lefeuvre-Plesse C, Diéras V, De la Motte Rouge T. Mol Oncol 18: 2024 2714-2729	3
Cooperative pro-tumorigenic adaptation to oncogenic RAS through epithelial-to-mesenchymal plasticity. De Blander H, Tonon L, Fauvet F, Pommier RM, Lamblot C, Benhassoun R, Angileri F, Gibert B, Rodriguez R, Ouzounova M, Morel AP, Puisieux A. Sci Adv 10: 2024 eadi1736	6
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity. Tan J, Egelston CA, Guo W, Stark JM, Lee PP. EBioMedicine 101: 2024 105035	5
MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases. Ito K, Harada I, Martinez C, Sato K, Lee E, Port E, Byerly JH, Nayak A, Tripathi E, Zhu J, Irie HY. Cancer Res Commun 4: 2024 946-957	5
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer. Alexander J, Schipper K, Nash S, Brough R, Kemp H, Iacovacci J, Isacke C, Natrajan R, Sawyer E, Lord CJ, Haider S. Br J Cancer 130: 2024 1828-1840	2
Mutational landscape of HSP family on human breast cancer. Fernandez-Muñoz JM, Guerrero-Gimenez ME, Ciocca LA, Germanó MJ, Zoppino FCM. Sci Rep 14: 2024 12471	0
Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study. Tjader NP, Beer AJ, Ramroop J, Tai MC, Ping J, Gandhi T, Dauch C, Neuhausen SL, Ziv E, Sotelo N, Ghanekar S, Meadows O, Paredes M, Gillespie JL, Aeilts AM, Hampel H, Zheng W, Jia G, Hu Q, Wei L, Liu S, Ambrosone CB, Palmer JR, Carpten JD, Yao S, Stevens P, Ho WK, Pan JW, Fadda P, Huo D, Teo SH, McElroy JP, Toland AE. Cancer Res Commun 4: 2024 1597-1608	2
Protocol for performing metabolic pathway-based subtyping of breast tumors. Iqbal MA, Smith K, Singh P, Siddiqui S, Chandrasekaran S. STAR Protoc 5: 2024 103173	0
Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis. Padmanaban V, Keller I, Seltzer ES, Ostendorf BN, Kerner Z, Tavazoie SF. Nature 633: 2024 207-215	36
CXCR6 expression correlates with radiotherapy response and immune context in triple-negative breast cancer-experimental studies. Meng J, Yang Y, Lv J, Lv H, Zhao X, Zhang L, Shi W, Yang Z, Mei X, Chen X, Ma J, Zhang Z, Shao Z, Yu X, Guo X. Int J Surg 110: 2024 4695-4707	4
Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features. Ingebriktsen LM, Humlevik ROC, Svanøe AA, Sæle AKM, Winge I, Toska K, Kalvenes MB, Davidsen B, Heie A, Knutsvik G, Askeland C, Stefansson IM, Hoivik EA, Akslen LA, Wik E. Breast Cancer Res 26: 2024 126	2
HCS-hierarchical algorithm for simulation of omics datasets. Stomma P, Rudnicki WR. Bioinformatics 40: 2024 ii98-ii104	0
Withaferin A decreases glycolytic reprogramming in breast cancer. Khan A, Rehman AU, Siddiqui S, Khan J, Massey S, Singh P, Saluja D, Husain SA, Iqbal MA. Sci Rep 14: 2024 23147	2
iSubGen generates integrative disease subtypes by pairwise similarity assessment. Fox NS, Tian M, Markowitz AL, Haider S, Li CH, Boutros PC. Cell Rep Methods 4: 2024 100884	0
A regularized Cox hierarchical model for incorporating annotation information in predictive omic studies. Shen D, Lewinger JP, Kawaguchi E. BioData Min 17: 2024 44	0
Integrative systems-level analysis reveals a contextual crosstalk between hypoxia and global metabolism in human breast tumors. Abou Khouzam R, Chouaib S, Iqbal MA. Mol Oncol 19: 2025 1725-1736	0
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets. Ellrott K, Wong CK, Yau C, Castro MAA, Lee JA, Karlberg BJ, Grewal JK, Lagani V, Tercan B, Friedl V, Hinoue T, Uzunangelov V, Westlake L, Loinaz X, Felau I, Wang PI, Kemal A, Caesar-Johnson SJ, Shmulevich I, Lazar AJ, Tsamardinos I, Hoadley KA, Cancer Genome Atlas Analysis Network, Robertson AG, Knijnenburg TA, Benz CC, Stuart JM, Zenklusen JC, Cherniack AD, Laird PW. Cancer Cell 43: 2025 195-212.e11	7
Complex rearrangements fuel ER<sup>+</sup> and HER2<sup>+</sup> breast tumours. Houlahan KE, Mangiante L, Sotomayor-Vivas C, Adimoelja A, Park S, Khan A, Pribus SJ, Ma Z, Caswell-Jin JL, Curtis C. Nature 638: 2025 510-518	5
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer. Ziegler DV, Parashar K, Leal-Esteban L, López-Alcalá J, Castro W, Zanou N, Martinez-Carreres L, Huber K, Berney XP, Malagón MM, Roger C, Berger MA, Gouriou Y, Paone G, Gallart-Ayala H, Sflomos G, Ronchi C, Ivanisevic J, Brisken C, Rieusset J, Irving M, Fajas L. Nat Commun 16: 2025 541	0
Preserving information while respecting privacy through an information theoretic framework for synthetic health data generation. Sella N, Guinot F, Lagrange N, Albou LP, Desponds J, Isambert H. NPJ Digit Med 8: 2025 49	1
Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling. Regner MJ, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B, Spanheimer PM, Parker JS, Perou CM, Franco HL. Cell Genom 5: 2025 100765	1
Distinct clinicopathological features and treatment differences in breast cancer patients of young age. Humlevik ROC, Svanøe AA, Aas T, Heie A, Sæle AKM, Akslen LA, Wik E, Hoivik EA. Sci Rep 15: 2025 5655	0
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. Felsheim BM, Fernandez-Martinez A, Fan C, Pfefferle AD, Hayward MC, Hoadley KA, Rashid NU, Tolaney SM, Somlo G, Carey LA, Sikov WM, Perou CM. NPJ Breast Cancer 11: 2025 24	0
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis. Røssevold AH, Tekpli X, Lingjærde OC, Russnes HG, Vallon-Christersson J, Borgen E, Lømo J, Garred Ø, Dorraji E, Kristensen VN, Naume B, Kyte JA. Commun Med (Lond) 5: 2025 234	0
Regular aspirin use, breast tumor characteristics and long-term breast cancer survival. Peng C, Wang T, Holmes MD, Chen WY, Brantley KD, Le PA, J Heng Y, Schedin PJ, Rosner BA, Willett WC, Stampfer MJ, Tamimi RM, Heather Eliassen A. NPJ Breast Cancer 11: 2025 62	0